'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Torrent Pharmaceuticals has increased 7.80% to Rs 2959 crore. Operating profit margin has jumped from 32.17% to 32.58%, leading to 9.17% rise in operating profit to Rs 964.00 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 14.69% to 13.20%. Purchase of finished goods cost rose from 11.29% to 13.66%. Employee cost increased from 17.41% to 18.42%. Other expenses fell from 24.97% to 23.08%.
PBIDT rose 3.50% to Rs 946 crore. Provision for interest fell 30% to Rs 56 crore. Loan funds declined from Rs 4,022.00 crore as of 31 March 2024 to Rs 3,202.00 crore as of 31 March 2025. Inventories rose to Rs 2,541.00 crore as of 31 March 2025 from Rs 2,279.00 crore as of 31 March 2024. &...
Pleaselogin & subscribe to view the full report.
More Reports
|
|